Prolynx is a biotechnology startup based in Emeryville, California. The company develops extended-duration therapeutics designed for once-monthly and once-quarterly dosing, focusing on obesity and related metabolic diseases. Prolynx was founded in 2010 by chemists Daniel Santi and Gary Ashley.
The company's technology platform centers on proprietary linker technology for ultra-long-acting therapeutics. Its initial priority is a long-acting version of semaglutide, along with a pipeline of extended-duration incretin and non-incretin therapies. The company raised $70 million in Series A funding led by 5AM Ventures, OrbiMed, and Monograph Capital in December 2025.
Recent Leadership News
Amer Mirza, Chief Scientific Officer, July 2026. Simon Harnest, Chief Financial Officer, July 2026.
Chris Boulton was appointed Chief Executive Officer in December 2025, bringing obesity and metabolic drug expertise from roles at Amgen, Sanofi, and AstraZeneca.
Facts compiled by Executive Moves from publicly available news and press releases on 17 July 2026. Spotted an inaccuracy? Email us and we'll review within 1 business day.
To upgrade to a Premium Profile reach out to us at info@executive-moves.com.
Are you on the Prolynx team?
This is a Light company page, auto-generated from public news coverage. Claim it to verify the company description, add logo and links, and control how your organisation is represented on Executive Moves.
Claim this company →
